摘要
目的比较二甲双胍格列吡嗪复方制剂及单药二甲双胍或格列吡嗪控制T2DM患者血糖达标前后APN水平的变化。方法将63例T2DM患者分为3组:A组23例,口服二甲双胍格列吡嗪复合制剂;B组18例,口服二甲双胍片;C组22例,口服格列吡嗪片。各组疗程均为12周。比较治疗前后空腹及餐后血糖、血清胰岛素、HbA1c、胰岛素抵抗指数(HOMA-IR)、APN等相关指标。结果治疗前后,A、B组APN升高(P<0.01),C组APN水平下降,但组间比较差异无统计学意义;3组间APN水平值比较显示,A组高于B、C组(P<0.05或P<0.01),B组高于C组(P<0.01);相关性分析显示,APN水平值与HOMA-IR、BMI呈负相关(r=-0.342,P<0.01;r=-0.336,P<0.01)。结论二甲双胍可能通过改善IR、控制体重进而降低BMI等途径来升高APN;二甲双胍格列吡嗪复方制剂改善APN可能是二甲双胍和格列吡嗪的协同作用,能升高血清APN水平。
Objective To detect the changes in plasma level of adiponectin in T2DM patients when their blood glucose was controlled with metformin or glipizide or the compound of the two. Methods Sixty-three T2DM patients were divided into three groups： Group A, 23 patients, treated with the compound metformin and glipizide; Group B, 18 patients, treated with metformin; and Group C, 22 patients, treated with glipizide, for 12 weeks. Comparison was made to observe the changes in the levels of fasting and postprandial glucose, insulin, HbAxc, HOMA-IR, HOMA-β, and serum adiponectin among the three groups after treatment. Results The patients in Group A and B got a significant increase in serum adiponectin （P〈0. 01）, the patients in group C got a decrease in serum adiponectin, although the difference was not significant. The change level of adiponectin in group A was significantly higher than in group B and C （P〈0. 05 or P〈0. 01）, and the change level of group B was higher than of group C （P〈0. 01）. The correlation analysis showed that the change level of adiponectin was negatively correlated with BMI and HOMA-IR （r=-0. 342, P^0. 01; r=-0. 336, P〈0. 01）. Conclusion Metfomain may increase adiponectin through improving HOMA-IR and decreasing BMI. The improved effects of compound glipizide and metformin on adiponeetin may be synergistic actions of glipizide and metformin.
出处
《中国糖尿病杂志》
CAS
CSCD
北大核心
2013年第4期293-295,共3页
Chinese Journal of Diabetes
基金
江苏省自然基金项目(BK2010121)
南京市卫生局基金项目(YKK10105)
关键词
二甲双胍格列吡嗪复合制剂
脂联素
糖尿病
2型
胰岛素抵抗指数
Compound glipizide and metformin
Adponectin
Diabetes mellitus, type 2
Homeostalic model assessment insulin resistance
